Multiple functional defects in platelets from thrombocytopenic cancer patients undergoing chemotherapy

Research output: Contribution to journalArticleAcademicpeer-review


Introduction severe thrombocytopenia (= 50 × 109 platelets/l) is often the consequence of hematological malignancies and intensive chemotherapy. The risk of clinically significant bleeding is increased in these patients, despite the use of prophylactic platelet transfusions. The fact that there is no clear correlation between the platelet count and the risk of hemorrhage, suggests that there are other contributing factors. The contribution of impairments in platelet and coagulant function remains poorly understood.
Original languageEnglish
Pages (from-to)S171-S171
JournalThrombosis Research
Publication statusPublished - Apr 2016

Cite this